A detailed history of Schonfeld Strategic Advisors LLC transactions in Arcutis Biotherapeutics, Inc. stock. As of the latest transaction made, Schonfeld Strategic Advisors LLC holds 30,349 shares of ARQT stock, worth $308,952. This represents 0.0% of its overall portfolio holdings.

Number of Shares
30,349
Previous 16,174 87.64%
Holding current value
$308,952
Previous $150,000 88.0%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$8.32 - $11.0 $117,936 - $155,925
14,175 Added 87.64%
30,349 $282,000
Q2 2024

Aug 14, 2024

BUY
$7.24 - $12.53 $117,099 - $202,660
16,174 New
16,174 $150,000
Q4 2022

Feb 14, 2023

BUY
$13.96 - $20.4 $392,276 - $573,240
28,100 New
28,100 $415,000
Q2 2022

Aug 15, 2022

SELL
$16.33 - $22.2 $293,874 - $399,511
-17,996 Closed
0 $0
Q1 2022

May 16, 2022

BUY
$14.38 - $22.79 $258,782 - $410,128
17,996 New
17,996 $347,000

Others Institutions Holding ARQT

About Arcutis Biotherapeutics, Inc.


  • Ticker ARQT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 60,187,500
  • Market Cap $613M
  • Description
  • Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing A...
More about ARQT
Track This Portfolio

Track Schonfeld Strategic Advisors LLC Portfolio

Follow Schonfeld Strategic Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Schonfeld Strategic Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Schonfeld Strategic Advisors LLC with notifications on news.